1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ContraFect Corp.

ContraFect Corp.

CFRXQ
ContraFect Corp.US flagOther OTC
0.00
USD
- -
- -
107.00Market Cap
ContraFect Corp.
CFRXQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-2,771.41
-1,765.9
-3,086.44
-861.46
-680.72
-223.29
-396.35
-123.56
-98.95
-44.12
-124.97
-5.62
Basic EPS, GAAP
-2,344.09
-1,050.87
-1,325.32
-760.97
-701.59
-352.97
-277.59
-265.09
-116.63
-89.46
-88.3
-8.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4,918.1
-4,324.22
-8,243.26
-4,031.98
-3,485.2
-2,325.78
-2,096.3
-2,048.55
-844.39
-566.79
-624.72
-79.11
Book Value per Share
-4,632.3
-3,955.63
2,280.8
1,051.94
465.43
448.87
58.29
150.13
44.35
107.41
-22.73
-1.34
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-19
-24
-30
-25
-29
-16
-38
-13
-28
-20
-65
-24
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3
-3
25
30
32
44
26
21
41
51
-3
-6
Working Capital
1
10
- -
- -
- -
- -
- -
3
3
3
2
2
LT Debt
-32
-13
26
31
20
31
6
16
13
49
-12
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
11
11
Market Capitalization
2
3
2

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
18
17
7
Cash, Cash Equivalents & STI
14
14
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
20
16
12
Payables & Accruals
17
14
10
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.6%
49.34%
-124%
Free Cash Flow
12.55%
13.67%
11.94%
Net Income, GAAP
39.16%
78.03%
221.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-14.35
-10.98
-10.76
-8.95
-44.12
2022
-41
-36.79
-34.72
-16.14
-124.97
2023
-0.69
-1.94
-0.5
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Comera Life Sciences Holdings, Inc. (CMRAW)
BrainAurora Medical Technology Limited (6681.HK)
Maravai LifeSciences Holdings, Inc. (MRVI)
Y-mAbs Therapeutics, Inc. (YMAB)
ReproCELL Incorporated (4978.T)
Imugene Limited (IMU.AX)
Business
ContraFect Corporation ContraFect Corporation, a clinical-stage biotechnology company founded in 2008 and headquartered in Yonkers, New York, discovers and develops direct lytic agents (DLAs), including lysins and amurin peptides, as novel therapeutics for life-threatening, antibiotic-resistant infectious diseases treated primarily in hospital settings. Its lead product candidates comprise exebacase (CF-301), a lysin targeting Staphylococcus aureus bacteremia including methicillin-resistant strains; CF-296, an engineered lysin for invasive Staphylococcal infections such as osteomyelitis, prosthetic joint infections, and biofilm-associated conditions; and CF-370, an anti-pseudomonal lysin for Pseudomonas aeruginosa infections like ventilator-associated pneumonia and bloodstream infections; alongside preclinical amurin peptides addressing Gram-negative ESKAPE pathogens. The company targets critical hospital-acquired infections in the United States, leveraging platforms that rapidly lyse bacterial cell walls without promoting resistance. In December 2023, ContraFect Corporation ceased operations and filed for Chapter 7 bankruptcy liquidation in the U.S. Bankruptcy Court for the District of Delaware, with assets listed at approximately $0.61 million and liabilities at $9.32 million, following Nasdaq delisting earlier that year due to failure to meet listing standards. Prior developments included a 2020 equity investment from Pfizer Inc. Pfizer Inc., up to $6.94 million in non-dilutive CARB-X funding for its amurin program in 2019, and preclinical advancements for Gram-negative lysins, though clinical progress such as Phase 3 enrollment for exebacase was halted amid futility concerns. No active subsidiaries or parent relationships are noted post-bankruptcy.